Human infections tick-transmitted

Panminerva Medica

Volumn 43, Issue 4, 2001, Pages 295-304

  Alciati, S ^a   Belligni, E ^a   Del Colle, S ^a   Pugliese, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Lyme disease; Rickettsia infections; Ticks; Viral encephalitis

Indexed keywords

ANIMAL; BABESIOSIS; COLORADO TICK FEVER; EHRLICHIOSIS; EUROPE; HUMAN; LYME DISEASE; NORTH AMERICA; REVIEW; RICKETTSIOSIS; TICK BORNE DISEASE; TICK BORNE ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER;

ANIMALS; BABESIOSIS; COLORADO TICK FEVER; EHRLICHIOSIS; ENCEPHALITIS, TICK-BORNE; EUROPE; HEMORRHAGIC FEVERS, VIRAL; HUMANS; LYME DISEASE; NORTH AMERICA; RICKETTSIA INFECTIONS; TICK-BORNE DISEASES;

EID: 0035650716     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. De Carneri I. Parassitologia generale ed umana. VIII edizione. Milano: Ambrosiana Ed, 1983:272-5.
2. White GB. Medical acarology and entomology. In: Cook GC, editor. Manson's tropical diseases. 20th edition. London: WB Saunders Company, 1996:1650-736.
3. Belman AL. Tick-borne diseases. Semin Pediatr Neurol 1999;6: 249-66.
4. Moroni M, Esposito R, De Lalla F, Manuale di malattie infettive. V edizione. Milano: Masson Ed, 1998:845-51.
5. Steere AC, Broderick TF, Malwista SE. Erythema chronicum migrans and Lyme arthritis. Epidemiologic evidence for a tick vector. Am J Epidemiol 1978;108:312-21.
6. Johnson R, Schmid GP, Hyde FW, Steigerwalt AC, Brenner DJ. Borrelia burgdorferi sp. nov.: etiologic agent of Lyme disease. Int J Syst Bacteriol 1984;34:496-7.
7. Postic D, Assous M, Belfaiza J, Baranton G. Genetic diversity of Borrelia of Lyme borreliosis. Wien Klin Wochenschr 1996;108:745-51.
8. Barbour AG. Fall and rise of Lyme disease and other isodex tick-borne infections in North America and Europe. Br Med Bull 1998;54: 647-58.
9. Hellström S. Erythema chronicum migrans Afzelii. Acta Dermatol Venereol (Stockh) 1930;11:315-21.
10. Dennis DT. Country report on Lyme disease: United States. In: Report of WHO workshop on Lyme borreliosis diagnosis and surveillance. Warsaw (Poland), 20-22 June 1996. WWHO/CDS/VPH/95. 141: 160-81.
11. Steere AC. Lyme disease: a growing threat to urban population- review. Proc Natl Acad Sci USA 1994;91:2378-83.
12. Berglund J, Eitrem R, Norrby SR. Llong-term study of Lyme borreliosis in a highly endemic area in Sweden. Scand J Infect Dis 1996; 28:473-8.
13. Report of WHO - Workshops on Lyme borreliosis: diagnosis and surveillance. Warsaw (Poland), 20-22 June 1996.
14. Strle F, Stantic-Pavlimic M. Lyme disease in Europe. N Engl J Med 1996;334:803.
15. Schwartz BS, Goldstein MD. Lyme disease in outdoor workers: risk factors, preventative measures, and tick removal methods. Am J Epidemiol 1990;131:877-85.
16. Kuiper H, van Dam AP, Moll van Charante AW. Nauta NP, Dankert J. One year follow-up study to assess the prevalence and incidence of Lyme borreliosis among Dutch forestry workers. Eur J Clin Microbiol Infect Dis 1993;12:413-8.
17. Vos K, van Dam AP, Kuiper H, Bruins H, Spanjaard L, Dankert J. Seroconversion for Lyme borreliosis among Dutch military. Scand J Infect Dis 1994;26:427-34.
18. Fidelus-Gort R, Gilmour RW, Kashtus WC. Serological responses in Lyme disease: the influence of sex, age and environment. Ann Clin Labor sci 1993;23:221-9.
19. Burkert S, Rossler D, Munchoff P, Wilske B. Development of enzyme-linked immunosorbent assay using recombinant borrelial antigens for serodiagnosis of Borrelia burgdorferi infections. Med Microbiol Immunol 1996;185:49-57.
20. Granström M. Tick-borne zoonoses in Europe. Clin Microbiol Infect 1997;3:156-69.
21. Dennis DT. Standardization of serological techniques for the diagnosis in humans in North America. In: report of WHO workshop on Lyme borreliosis diagnosis and surveillance. Warsaw (Poland), 20-22 June 1996, WHO/CDS/VPH/95 141:209-14.
22. Nadelman RB, Wormser GP. Lyme borreliosis. Lancet 1998;15:557-65.
23. Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology and treatment of infections in humans and experimental animals. Clin Infect Dis 1998; 26:151-64.
24. Haglund M, Forsgren M, Lindh G, Lindquist L. A 10-year follow-up of tick-borne encephalitis in the Stockholm area and a review of the literature. Need for a vaccination strategy. Scand J Infect Dis 1996;28: 217-24.
25. Christmann D, Staub-Schmidt T. Tick-borne encephalitis in Central and Eastern Europe. Presse Med 1996;25:420-3.
26. Wahlberg P, Salminen A, Weckström P, Oker-Blom N. Diphasic tick-borne meningoencephalitis, Kumlinge disease, in the Aland islands. Acta Med Scand 1964;412(s):275-86.
27. Kaiser R. Tick-borne encephalitis in southern Germany. Lancet 1995; 345:463-4.
28. Wahlerg P, Saikku P, Brummer-Korvenkontio M. Tick-borne viral encephalitis in Finland. The clinical features of Kumlinge disease during 1959-1987. J Intern Med 1989;225:173-7.
29. Kunz C, Moritsch H. Zur serologischen diagnostik der Frühsommermeningoenzephalitis (FSME). Arch Gesamte Virusforsch 1961;11: 568-72.
30. Holzmann H, Kundi M, Stiasny K, Clement J, Mc Kenna P, Kunz C et al. Correlation between ELISA, hemagglutination inhibition and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol 1996;48:102-7.
31. Kaiser R, Holzmann H. Laboratory findings in tick-borne encephalitis-correlation with clinical outcome. Infection 2000;28:78-84.
32. Klockman U, Krivanec K, Stephenson JR, Hilfenhaus J. Protection against European isolates of tick-borne encephalitis after vaccination with a new tick-borne encephalitis vaccine. Vaccine 1991;9: 210-2.
33. Von Hedenström M, Hederle U, Theobald K. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse effects. Vaccine 1995;13:759-62.
34. Florio L, Steward MO, Muarage ER. The experimental transmission of Colorado tick fever. J Exp Med 1944;80:165-72.
35. Tsai TF. Arboviral infections in the United States (Review). Infect Dis Clin N Am 1991;5:73-102.
36. Phillipp CP, Callaway C, Chu M, Huang GH, Monath TP, Trent D et al. Replication of Colorado tick fever virus within human hematopoietic progenitor cells. J Virol 1993;67:2389-95.
37. Tsai TF. Colorado tick fever. In: Conn RB, editor. Current diagnosis. Philadelphia: WB Saunders, 1991:227-35.
38. Attoui H, Billoir F, Bruey JM, de Micco P, de Lamballerie X. Serologic and molecular diagnosis of Colorado tick fever viral infections. Am J Trop Med Hyg 1998;59:763-8.
39. Calisher CH. Medically important arboviruses of the United States and Canada (Review). Clin Microbiol Rev 1994;7:89-116.
40. Moroni M, Esposito R, De Lalla F. Manuale di malattie infettive. Milano: Masson Ed., 1998:283-8.
41. Hackstadt T. The biology of Rickettsiae. Infect Agents Dis 1996; 5:127-43.
42. Marrero M, Raoult D. Centrifugation shell vial technique for rapid detection of Mediterranean spotted fever rickettsia in blood culture. Am J Trop Med Hyg 1989;40:197-9.
43. Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory and epidemiological features of 262 cases. J Infect Dis 1984;150:480-8.
44. Zhou L, Fan M, Chen J, Cai H, Zhou F, Zhu H. Analysis of fatty acid composition of spotted lever group rickettsiae isolated in China by gas chromatography. Wei Sheng Wu Hsueh Pao 1993;33:290-6.
45. Wolbach SB. Studies of Rocky Mountain spotted fever. J Med Res 1914;41:2-197.
46. Raoult D, Rova V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 1997;10:694-719.
47. Weiss E. History of rickettsiology. In. Walker DH, editor. Biology of Rickettsial diseases. Boca Raton FL: CRC Press. 1988;1:15-32.
48. Tigertt WD. A 1759 spotted fever epidemic in North Carolina. J Hist Med Allied Sci 1987;42:296-304.
49. Anacker RL, Mann RE, Gonzales C. Reactivity of monoclonal antibodies to Rickettsia rickettsi with spotted fever and typhus group rickettsiae. J Clin Microbiol 1987;25:167-71.
50. Burgdorfer W. Ecological and epidemiological considerations of Rocky Mountain spotted fever and scrub typhus. In: Walker DH, editor. Biology of rickettsial diseases. Boca Raton FL: CRC Press, 1988: 33-50.
51. Centers for Disease Control and Prevention. Rocky Mountain spotted fever and human ehrlichiosis - United States. 1989. MMWR 1990;39: 281-4.
52. Walker DH. Tick-transmitted infections diseases in the United States. Annu Rev Ptibl Health. CDC Atlanta. 1998;19:237-69.
53. Azad AF, Beartd CB. Rickettsial pathogens and their arthropod vectors. Emerg Infect Dis 1998;4:179-86.
54. Walker DH. Pathology and pathogenesis of the vasculotropic rickettsioses. In: Walker DH, editor. Biology of rickettsial diseases. Boca Raton, FL: CRC Press, 1988;1:115-38.
55. Kapiowitz LG, Fischer JJ, Sparling PF. Rocky Mountain spotted fever: a clinical dilemma. In: Remington JB, Swartz HN, editors. Current clinical topics in infectious diseases. New York: Mc Graw-Hill, 1981:89-108.
56. Walker DH, Mattern WD. Acute renal failure in Rocky Mountain spotted fever. Arch Intern Med 1979;139:443-8.
57. Archibald LK, Sexton DJ. Long-term sequealae of rocky Mountain spotted fever. Clin Infect Dis 1995;20:1122-5.
58. Teysseire N, Raoult D. Comparison of the western immunoblot and microimmunofluorescence for diagnosis of Mediterranean spotted fever. J Clin Microbiol 1992;30:455-60.
59. Segura-Porta F, Diestre-Ortin G, Ortuno-Romero A, Sanfeliu-Sala I, Font-Creus B, Munoz-Espin T et al. Prevalence of antibodies to spotted fever group rickettsiae in human beings and dogs from and endemic area of mediterranean spotted fever in Catalonia, Spain. Eur J Epidemiol 1998;14:395-8.
60. Walker DH, Gear JM. Correlation of the distribution of Rickettsia conorii microscopic lesions and clinical features in South African Tick bite fever. Am J Trop Med Hyg 1985;34:361-71.
61. Buscemi S, D'Orio L, Sgroi C. Clinical characteristics and therapeutic perspectives of botonneuse. Assessment of a caseload of 39 patients. Ann Ital Med Int 1997;12:11-4.
62. Ruiz-Beltran R, Herrero-Herrero JI. Evaluation of ciprofloxacin and doxycycline in the treatment of Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 1992;11:427-31.
63. Raoult D, Drancourt M. Antimicrobial therapy of rickettsial diseases. Antimicrob Agents Chemother 1991;35:2457-62.
64. Dumler JS, Bakken JS. Ehrlichial disease of humans: emerging tick-borne infections. Clin Infect Dis 1995;20:1102-10.
65. Scaffner W, Standaert SM. Ehrlichiosis in pursint of an emerging infection. N Engl J Med 1996;334:262-3.
66. Brouqui P, Dumler JS, Lienhard R, Brossard M, Raoult D. Human granulocytic ehrlichiosis in Europe. Lancet 1995;346:782-3.
67. Rikihisa Y. Clinical and biological aspects of infection caused by Ehrlichia caffeensis. Microbes Infect 1999;1:367-76.
68. Klein MB, Hu S, Chao CC, Goodmann JL. The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. J Infect Dis 2000;182:200-5.
69. Rikihisa Y. Diagnosis of emerging ehrlichial diseases of dogs, horses and humans. J Vet Intern Med 2000;14:250-1.
70. Standaert SM, Yu T, Scott MA, Childs JE, Paddock CD, Nicholson WL et al. Primary isolation of ehrlichia chaffeensis from patients with febbrile illnesses: clinical and molecular characteristics. J Infect Dis 2000;181:1082-8.
71. Perdizet GA, Olson NH, Krause PJ, Banever GT, Spielman A, Cable RG. Babesiosis in a renal transplant recipient acquired through blood transfusion. Transplantation 2000;70:205-8.
72. Homer MJ, Aguilar-Delfin I, Telford SR, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev 2000;13:451-69.
73. Wijaya A, Wulansari R, Ato H, Inokuma H, Makimura S. Therapeutic effect of clindamycin and tetracycline on Babesia rodhaini infection in mouse model. J Vet Med Sci 2000;62:835-9.
74. Krause PJ, Lepore T, Sikand VK, Gadbaw JJ jr, Burke G, Telford SR et al. Atovaquone and azithromycin for treatment of babesiosis. N Engl J Med 2000;343:1454-8.
75. Mc Govern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol 1999;135:311-22.
76. Berdal BP, Mehl R, Haaheim H, Loksa M, Grunow R, Burans J et al. Field detection of Francisella tularensis. Scand infect Dis 2000;32:287-91.
77. Duenas AI, Ortega M, Garrote I, de Frutos M, Gutierrez P, Garcia-Pascual A et al. Laboratory diagnosis course in patients with tularemia. Med Clin (Bare) 2000;114:407-10.
78. Ikaheimo I, Syrjala H, Karhukorpi J, Scildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000;46:278-90.